BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32569833)

  • 1. Exportin 1 inhibition as antiviral therapy.
    Uddin MH; Zonder JA; Azmi AS
    Drug Discov Today; 2020 Oct; 25(10):1775-1781. PubMed ID: 32569833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
    Kashyap T; Murray J; Walker CJ; Chang H; Tamir S; Hou B; Shacham S; Kauffman MG; Tripp RA; Landesman Y
    Antiviral Res; 2021 Aug; 192():105115. PubMed ID: 34157321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.
    Perwitasari O; Johnson S; Yan X; Howerth E; Shacham S; Landesman Y; Baloglu E; McCauley D; Tamir S; Tompkins SM; Tripp RA
    J Virol; 2014 Sep; 88(17):10228-43. PubMed ID: 24965445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How SARS-CoV-2 and Other Viruses Build an Invasion Route to Hijack the Host Nucleocytoplasmic Trafficking System.
    Sajidah ES; Lim K; Wong RW
    Cells; 2021 Jun; 10(6):. PubMed ID: 34200500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
    Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
    EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
    Lai C; Xu L; Dai S
    Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importins and exportins as therapeutic targets in cancer.
    Mahipal A; Malafa M
    Pharmacol Ther; 2016 Aug; 164():135-43. PubMed ID: 27113410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas.
    Saenz-Ponce N; Pillay R; de Long LM; Kashyap T; Argueta C; Landesman Y; Hazar-Rethinam M; Boros S; Panizza B; Jacquemyn M; Daelemans D; Gannon OM; Saunders NA
    Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the nuclear transport machinery by rational drug design.
    Mao L; Yang Y
    Curr Pharm Des; 2013; 19(12):2318-25. PubMed ID: 23082981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication
    Jorquera PA; Mathew C; Pickens J; Williams C; Luczo JM; Tamir S; Ghildyal R; Tripp RA
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30541831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hippo kinase STK38 ensures functionality of XPO1.
    Martin AP; Camonis JH
    Cell Cycle; 2020 Nov; 19(22):2982-2995. PubMed ID: 33017560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication.
    Mathew C; Tamir S; Tripp RA; Ghildyal R
    Sci Rep; 2021 Sep; 11(1):19223. PubMed ID: 34584169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CRM1-mediated nuclear export of influenza A nucleoprotein and nuclear export protein as a novel target for antiviral drug development.
    Chutiwitoonchai N; Mano T; Kakisaka M; Sato H; Kondoh Y; Osada H; Kotani O; Yokoyama M; Sato H; Aida Y
    Virology; 2017 Jul; 507():32-39. PubMed ID: 28399435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
    Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
    PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
    Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
    Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.